EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects

Yibing Hu, Zhenping Wu, Xiaoyun Yang, Jin Ding, Qunying Wang, Hao Fang, Lujian Zhu, Minli Hu

BMC Microbiology · 2024

DOI: 10.1186/s12866-024-03705-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMC Microbiology, 2024. Verfasst von Yibing Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, No.365 Renming East Road, Jinhua, Zhejiang, P. R.…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Latent Tuberculosis, Colitis, Ulcerative, Antitubercular Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Health of Zhejiang Province, Science and Technology Plan Project of Jinhua Municipal Central Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The gut microbiota plays a pivotal role in ulcerative colitis (UC) development. This study explores the impact of latent tuberculosis infection (LTBI) on the gut microbiota in UC and assesses changes during vedolizumab treatment, investigating prophylactic anti-tuberculosis therapy. RESULTS: This cohort study included adult patients with UC receiving vedolizumab treatment at Jinhua Hospital, Zhejiang University from April 2021 to December 2022. Patients were divided into LTBI (n = 24) and non-LTBI (n = 21) groups. Patients in the LTBI group were further subdivided into prophylactic (n = 13) and non-prophylactic (n = 11) groups. Clinical and fecal samples were collected pre- and post-vedolizumab treatment for the LTBI groups and pre-treatment for the non-LTBI group. The gut microbiota was analyzed using 16 S rRNA sequencing. Patients in the non-LTBI group exhibited higher diversity indices. Vedolizumab demonstrated efficacy in the LTBI group, with clinical response and remission rates of 83.3% and 75.0%, respectively. The gut microbiota diversity in the LTBI group increased post-vedolizumab treatment, and receiving prophylactic isoniazid showed no significant difference in vedolizumab treatment response compared to not receiving prophylactic isoniazid. Microbiota changes were similar between groups, with an increase in [Ruminococcus] expression after vedolizumab treatment. CONCLUSIONS: This cohort study, conducted at a single center, highlights that LTBI can reduce gut microbiota diversity among adult patient with UC. The observed efficacy of vedolizumab treatment in the LTBI group indicates a potential association with microbiota changes. However, mono-isoniazid exhibited limited impact, underscoring the potential of vedolizumab as a promising candidate for prophylactic anti-tuberculosis treatment in the context of UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeLatent TuberculosisColitis, UlcerativeAntitubercular AgentsAntibiotic ProphylaxisAntibodies, Monoclonal, HumanizedHumansMaleFemaleAdultAgedGastrointestinal AgentsBiodiversityRNA, Ribosomal, 16SCohort StudiesIsoniazid

Stichwörter der Autor:innen

Gut microbiotaLatent tuberculosis infectionProphylactic treatmentUlcerative colitisVedolizumab

Substanzen

vedolizumabGastrointestinal AgentsRNA, Ribosomal, 16SAntitubercular AgentsIsoniazidAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, No.365 Renming East Road, Jinhua, Zhejiang, P. R. China.
  • Department of Traumatology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, P. R. China.
  • Department of Infection, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, P. R. China.
  • Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, No.365 Renming East Road, Jinhua, Zhejiang, P. R. China. minlihu2024@163.com.

Förderung

  • Department of Health of Zhejiang Province
  • Science and Technology Plan Project of Jinhua Municipal Central Hospital

Zitieren

APA

Hu, Y., Wu, Z., Yang, X., Ding, J., Wang, Q., Fang, H., Zhu, L., & Hu, M. (2024). Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects. BMC Microbiology. https://doi.org/10.1186/s12866-024-03705-7

Vancouver

Hu Y, Wu Z, Yang X, Ding J, Wang Q, Fang H, et al. Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects. BMC Microbiology. 2024. doi:10.1186/s12866-024-03705-7

BibTeX
@article{Hu2024,
  author = {Hu, Yibing and Wu, Zhenping and Yang, Xiaoyun and Ding, Jin and Wang, Qunying and Fang, Hao and Zhu, Lujian and Hu, Minli},
  title = {Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects},
  journal = {BMC Microbiology},
  year = {2024},
  doi = {10.1186/s12866-024-03705-7}
}
Kostenlos starten →